Examination should at least include, apart from the HER2 expression, the status of microsatellite instability MSS and the expression of PDL1 in tumor tissue along with calculation of the combined positive score (CPS) and tumor proportion score (TPS), in order to facilitate the addition of immunotherapy agents. The gene discussed is ERBB2; the disease is neoplasm.